Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome

被引:25
作者
Ge, Mengyuan [1 ,2 ]
Molina, Judith [1 ,2 ]
Kim, Jin-Ju [1 ,2 ]
Mallela, Shamroop K. [1 ,2 ]
Ahmad, Anis [3 ]
Varona Santos, Javier [1 ,2 ]
Al-Ali, Hassan [1 ,2 ]
Mitrofanova, Alla [1 ,2 ]
Sharma, Kumar [4 ]
Fontanesi, Flavia [5 ]
Merscher, Sandra [1 ,2 ]
Fornoni, Alessia [1 ,2 ]
机构
[1] Univ Miami, Dept Med, Miller Sch Med, Katz Family Div Nephrol & Hypertens, Miami, FL 33136 USA
[2] Univ Miami, Peggy & Harold Katz Family Drug Discovery Ctr, Miller Sch Med, Miami, FL 33136 USA
[3] Univ Miami, Dept Radiat Oncol, Miller Sch Med, Miami, FL USA
[4] Univ Texas Hlth San Antonio, Ctr Precis Med, Sch Med, San Antonio, TX USA
[5] Univ Miami, Dept Biochem & Mol Biol, Miami, FL USA
来源
ELIFE | 2023年 / 12卷
基金
美国国家卫生研究院;
关键词
Alport syndrome; lipid; energy substrate; SGLT2; inhibitor; Mouse; COTRANSPORTER; 2; INHIBITION; FATTY-ACID OXIDATION; DIABETIC KIDNEY; CELL-LINES; SGLT2; METABOLISM; EXPRESSION; MUTATIONS; APOPTOSIS; DISEASE;
D O I
10.7554/eLife.83353
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are anti-hyperglycemic agents that prevent glucose reabsorption in proximal tubular cells. SGLT2i improves renal outcomes in both diabetic and non-diabetic patients, indicating it may have beneficial effects beyond glycemic control. Here, we demonstrate that SGLT2i affects energy metabolism and podocyte lipotoxicity in experimental Alport syndrome (AS). In vitro, we found that the SGLT2 protein was expressed in human and mouse podocytes to a similar extent in tubular cells. Newly established immortalized podocytes from Col4a3 knockout mice (AS podocytes) accumulate lipid droplets along with increased apoptosis when compared to wild-type podocytes. Treatment with SGLT2i empagliflozin reduces lipid droplet accumulation and apoptosis in AS podocytes. Empagliflozin inhibits the utilization of glucose/pyruvate as a metabolic substrate in AS podocytes but not in AS tubular cells. In vivo, we demonstrate that empagliflozin reduces albuminuria and prolongs the survival of AS mice. Empagliflozin-treated AS mice show decreased serum blood urea nitrogen and creatinine levels in association with reduced triglyceride and cholesterol ester content in kidney cortices when compared to AS mice. Lipid accumulation in kidney cortices correlates with a decline in renal function. In summary, empagliflozin reduces podocyte lipotoxicity and improves kidney function in experimental AS in association with the energy substrates switch from glucose to fatty acids in podocytes.
引用
收藏
页数:22
相关论文
共 50 条
  • [1] Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome
    Ge, Mengyuan
    Molina, Judith
    Tamayo, Ian
    Zhang, Guanshi
    Kim, Jin-Ju
    Njeim, Rachel
    Fontanesi, Flavia
    Pieper, Michael Paul
    Merscher, Sandra
    Sharma, Kumar
    Fornoni, Alessia
    KIDNEY360, 2024, 5 (07): : 1002 - 1011
  • [2] Discoidin domain receptor 1 activation links extracellular matrix to podocyte lipotoxicity in Alport syndrome
    Kim, Jin-Ju
    David, Judith M.
    Wilbon, Sydney S.
    Santos, Javier, V
    Patel, Devang M.
    Ahmad, Anis
    Mitrofanova, Alla
    Liu, Xiaochen
    Mallela, Shamroop K.
    Ducasa, Gloria M.
    Ge, Mengyuan
    Sloan, Alexis J.
    Al-Ali, Hassan
    Boulina, Marcia
    Mendez, Armando J.
    Contreras, Gabriel N.
    Prunotto, Marco
    Sohail, Anjum
    Fridman, Rafael
    Miner, Jeffrey H.
    Merscher, Sandra
    Fornoni, Alessia
    EBIOMEDICINE, 2021, 63
  • [3] Progress in therapeutic targets on podocyte for Alport syndrome
    Zheng, Qimin
    Gu, Xiangchen
    He, John Cijiang
    Xie, Jingyuan
    JOURNAL OF TRANSLATIONAL INTERNAL MEDICINE, 2024, 12 (02) : 129 - 133
  • [4] Podocyte p53 Limits the Severity of Experimental Alport Syndrome
    Fukuda, Ryosuke
    Suico, Mary Ann
    Kai, Yukari
    Omachi, Kohei
    Motomura, Keishi
    Koga, Tomoaki
    Komohara, Yoshihiro
    Koyama, Kosuke
    Yokota, Tsubasa
    Taura, Manabu
    Shuto, Tsuyoshi
    Kai, Hirofumi
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2016, 27 (01): : 144 - 157
  • [5] Accelerated podocyte detachment and progressive podocyte loss from glomeruli with age in Alport Syndrome
    Ding, Fangrui
    Wickman, Larysa
    Wang, Su Q.
    Zhang, Yanqin
    Wang, Fang
    Afshinnia, Farsad
    Hodgin, Jeffrey
    Ding, Jie
    Wiggins, Roger C.
    KIDNEY INTERNATIONAL, 2017, 92 (06) : 1515 - 1525
  • [6] Podocyte Depletion in Thin GBM and Alport Syndrome
    Wickman, Larysa
    Hodgin, Jeffrey B.
    Wang, Su Q.
    Afshinnia, Farsad
    Kershaw, David
    Wiggins, Roger C.
    PLOS ONE, 2016, 11 (05):
  • [7] Effect of disease progression on the podocyte cell cycle in Alport Syndrome
    Frank, Camille Nicolas
    Hou, Xiaogang
    Petrosyan, Astgik
    Villani, Valentina
    Zhao, Rui
    Hansen, Joshua R.
    Clair, Geremy
    Salem, Fadi
    De Filippo, Roger E.
    Cravedi, Paolo
    Lemley, Kevin, V
    Perin, Laura
    KIDNEY INTERNATIONAL, 2022, 101 (01) : 106 - 118
  • [8] Ezetimibe Enhances Lipid Droplet and Mitochondria Contact Formation, Improving Fatty Acid Transfer and Reducing Lipotoxicity in Alport Syndrome Podocytes
    Kim, Jin-Ju
    Yang, Eun-Jeong
    David, Judith Molina
    Cho, Sunjoo
    Ficarella, Maria
    Pape, Nils
    Schiffer, Josephin Elizabeth
    Njeim, Rachel
    Kim, Stephanie S.
    Lo Re, Claudia
    Fontanella, Antonio
    Kaber, Maria
    Sloan, Alexis
    Merscher, Sandra
    Fornoni, Alessia
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (23)
  • [9] Podocyte Lipotoxicity in CKD
    Kim, Jin-Ju
    Wilbon, Sydney S.
    Fornoni, Alessia
    KIDNEY360, 2021, 2 (04): : 755 - 762
  • [10] Alport syndrome: an update
    Savige, Judy
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2025, 34 (03) : 206 - 211